# LMO2

## Overview
LMO2 (LIM domain only 2) is a gene that encodes a protein crucial for various biological processes, particularly in hematopoiesis and angiogenesis. The LMO2 protein is characterized by its two LIM domains, which are zinc-binding motifs that facilitate protein-protein interactions, allowing it to function as a transcriptional regulator. It plays a pivotal role in the formation of multiprotein complexes that regulate gene expression during blood cell development, acting as a transcriptional co-regulator in erythroid cells. LMO2 is also involved in angiogenesis, contributing to the remodeling of the capillary network. Clinically, LMO2 is significant due to its association with hematological malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL), where its aberrant expression is linked to oncogenesis. The gene's dysregulation has implications in gene therapy, particularly in cases where retroviral vector integration near the LMO2 locus can lead to leukemia (Ruggero2016LMO2; HaceinBeyAbina2003LMO2).

## Structure
The LMO2 protein is characterized by its two LIM domains, which are zinc-binding and cysteine-rich structures essential for protein-protein interactions (Rabbitts1998LMO; Sewell2014Conformational). Each LIM domain contains two LIM fingers, which are structurally similar to DNA-binding GATA fingers, although LIM domains do not directly interact with DNA (Rabbitts1998LMO). The primary structure of LMO2 includes sequences that form these LIM domains, with zinc ions coordinated in a tetrahedral geometry by cysteine and histidine or aspartic acid residues (Sewell2014Conformational).

The secondary structure of LMO2 includes a central short alpha-helical region between the LIM domains, which contributes to its conformational flexibility (Sewell2014Conformational). The tertiary structure involves the folding of the LIM domains, with a hinge region providing motional flexibility that facilitates interactions with other proteins (Sewell2014Conformational).

In terms of quaternary structure, LMO2 forms multi-protein transcription complexes by interacting with proteins such as LDB1, TAL1/SCL, E47, and GATA1, acting as a bridging factor within these complexes (Sewell2014Conformational; Stanulović2017LMO2). The conformational flexibility of LMO2 is crucial for its role in these complexes, allowing it to mediate associations with a broad range of natural protein partners (Sewell2014Conformational).

## Function
The LMO2 gene encodes a protein that plays a critical role in hematopoiesis and angiogenesis. In healthy human cells, LMO2 is involved in the formation of multiprotein complexes that regulate gene expression during the development of blood cells. It acts as a transcriptional co-regulator, particularly in erythroid cells, where it forms a complex with Tal1/Scl, E47, Ldb1, and GATA-1 to bind specific DNA sequences, facilitating erythroid differentiation (Yamada2000The; Felli2009MicroRNA).

LMO2 is essential for the proper development and function of hematopoietic stem cells, contributing to the differentiation and maturation of various blood cell lineages. It is expressed in early hematopoietic precursors and is crucial for erythropoiesis, the process of red blood cell formation (Felli2009MicroRNA; Jevremovic2016LMO2). The protein is primarily active in the nucleus, where it influences cell differentiation and proliferation by interacting with other transcription factors (HaceinBeyAbina2003LMO2).

In addition to its role in hematopoiesis, LMO2 is involved in angiogenesis, where it is necessary for the remodeling of the capillary network into mature vasculature, although it is not required for the initial formation of capillaries from mesoderm (Yamada2000The).

## Clinical Significance
The LMO2 gene is clinically significant due to its role in various hematological malignancies. Aberrant expression of LMO2 is linked to T-cell acute lymphoblastic leukemia (T-ALL) and other lymphoproliferative disorders. In the context of gene therapy for X-linked severe combined immunodeficiency (SCID-X1), retroviral vector integration near the LMO2 locus has been associated with clonal T-cell proliferation and leukemia. This integration can lead to the overexpression of LMO2, contributing to oncogenesis by acting as an enhancer for the LMO2 promoter (HaceinBeyAbina2003LMO2).

LMO2 is also implicated in leukemogenesis through chromosomal translocations, such as t(11;14) and t(7;11), which are observed in T-ALL. Transgenic mouse models have shown that LMO2 overexpression can lead to T-cell leukemia, indicating its role as an oncogene in T-cell neoplasia (Ruggero2016LMO2; HaceinBeyAbina2003LMO2). In addition, LMO2 overexpression is associated with lymphoblastic lymphoma and is considered a marker for transformed T-cell precursors (Zanelli2021TCell).

The gene's activation is often accompanied by other genetic alterations, such as NOTCH1 mutations and CDKN2A deletions, which further contribute to the development of leukemia (Howe2008Insertional). These findings underscore the potential risks associated with LMO2 dysregulation in gene therapy and its role in hematological malignancies.

## Interactions
LMO2 (LIM domain only 2) is a transcriptional regulator that participates in various protein-protein interactions, forming multiprotein complexes essential for its function in hematopoiesis and oncogenesis. LMO2 interacts with proteins such as TAL1/SCL, LDB1, and GATA1, forming a DNA-binding complex that recognizes specific DNA sequences in erythroid cells (Appert2009Targeting). In T-cell tumors, LMO2 is part of a complex that binds tandem E boxes, involving interactions with TAL1/SCL and E47, facilitated by LDB1 (Sewell2014Conformational).

The protein's interactions are mediated through its two LIM domains, which are zinc-binding motifs. These domains allow LMO2 to bind directly to several basic-helix-loop-helix (bHLH) proteins, such as TAL1/SCL, TAL2, and LYL1, but not directly to E2A bHLH proteins like E12 or E47. Instead, LMO2 forms a complex with E47 through its interaction with TAL1/SCL, which heterodimerizes with E47 (Sewell2014Conformational).

LMO2's interactions can be disrupted by peptide aptamers and intracellular antibodies, which bind to its LIM domains, preventing the formation of functional transcription complexes. For instance, the peptide aptamer PA207 binds specifically to the second LIM domain of LMO2, inhibiting its role in T-cell neoplasia (Appert2009Targeting). These interactions highlight LMO2's role in transcription regulation and its potential as a therapeutic target in cancer.


## References


[1. (Stanulović2017LMO2) Vesna S. Stanulović, Pierre Cauchy, Salam A. Assi, and Maarten Hoogenkamp. Lmo2 is required for tal1 dna binding activity and initiation of definitive haematopoiesis at the haemangioblast stage. Nucleic Acids Research, 45(17):9874–9888, June 2017. URL: http://dx.doi.org/10.1093/nar/gkx573, doi:10.1093/nar/gkx573. This article has 22 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkx573)

[2. (Ruggero2016LMO2) K Ruggero, O Al-Assar, J S Chambers, R Codrington, T Brend, and T H Rabbitts. Lmo2 and il2rg synergize in thymocytes to mimic the evolution of scid-x1 gene therapy-associated t-cell leukaemia. Leukemia, 30(9):1959–1962, May 2016. URL: http://dx.doi.org/10.1038/leu.2016.116, doi:10.1038/leu.2016.116. This article has 10 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/leu.2016.116)

[3. (HaceinBeyAbina2003LMO2) S. Hacein-Bey-Abina, C. Von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C. S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J. I. Cohen, G. de Saint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A. Fischer, and M. Cavazzana-Calvo. Lmo2 -associated clonal t cell proliferation in two patients after gene therapy for scid-x1. Science, 302(5644):415–419, October 2003. URL: http://dx.doi.org/10.1126/science.1088547, doi:10.1126/science.1088547. This article has 2861 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1088547)

[4. (Yamada2000The) Yoshihiro Yamada, Richard Pannell, Alan Forster, and Terence H. Rabbitts. The oncogenic lim-only transcription factor lmo2 regulates angiogenesis but not vasculogenesis in mice. Proceedings of the National Academy of Sciences, 97(1):320–324, January 2000. URL: http://dx.doi.org/10.1073/pnas.97.1.320, doi:10.1073/pnas.97.1.320. This article has 143 citations.](https://doi.org/10.1073/pnas.97.1.320)

[5. (Felli2009MicroRNA) N. Felli, F. Pedini, P. Romania, M. Biffoni, O. Morsilli, G. Castelli, S. Santoro, S. Chicarella, A. Sorrentino, C. Peschle, and G. Marziali. Microrna 223-dependent expression of lmo2 regulates normal erythropoiesis. Haematologica, 94(4):479–486, April 2009. URL: http://dx.doi.org/10.3324/haematol.2008.002345, doi:10.3324/haematol.2008.002345. This article has 112 citations.](https://doi.org/10.3324/haematol.2008.002345)

[6. (Howe2008Insertional) Steven J. Howe, Marc R. Mansour, Kerstin Schwarzwaelder, Cynthia Bartholomae, Michael Hubank, Helena Kempski, Martijn H. Brugman, Karin Pike-Overzet, Stephen J. Chatters, Dick de Ridder, Kimberly C. Gilmour, Stuart Adams, Susannah I. Thornhill, Kathryn L. Parsley, Frank J.T. Staal, Rosemary E. Gale, David C. Linch, Jinhua Bayford, Lucie Brown, Michelle Quaye, Christine Kinnon, Philip Ancliff, David K. Webb, Manfred Schmidt, Christof von Kalle, H. Bobby Gaspar, and Adrian J. Thrasher. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of scid-x1 patients. Journal of Clinical Investigation, 118(9):3143–3150, September 2008. URL: http://dx.doi.org/10.1172/jci35798, doi:10.1172/jci35798. This article has 1015 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci35798)

[7. (Appert2009Targeting) Alex Appert, Chang-Hoon Nam, Natividad Lobato, Eva Priego, Ricardo Nunez Miguel, Tom Blundell, Lesley Drynan, Helen Sewell, Tomoyuki Tanaka, and Terence Rabbitts. Targeting lmo2 with a peptide aptamer establishes a necessary function in overt t-cell neoplasia. Cancer Research, 69(11):4784–4790, June 2009. URL: http://dx.doi.org/10.1158/0008-5472.can-08-4774, doi:10.1158/0008-5472.can-08-4774. This article has 33 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-08-4774)

[8. (Sewell2014Conformational) H. Sewell, T. Tanaka, K. El Omari, E. J. Mancini, A. Cruz, N. Fernandez-Fuentes, J. Chambers, and T. H. Rabbitts. Conformational flexibility of the oncogenic protein lmo2 primes the formation of the multi-protein transcription complex. Scientific Reports, January 2014. URL: http://dx.doi.org/10.1038/srep03643, doi:10.1038/srep03643. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep03643)

[9. (Rabbitts1998LMO) Terence H. Rabbitts. Lmo t-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes &amp; Development, 12(17):2651–2657, September 1998. URL: http://dx.doi.org/10.1101/gad.12.17.2651, doi:10.1101/gad.12.17.2651. This article has 138 citations.](https://doi.org/10.1101/gad.12.17.2651)

[10. (Jevremovic2016LMO2) Dragan Jevremovic, Anja C. Roden, Rhett P. Ketterling, Paul J. Kurtin, and Ellen D. McPhail. Lmo2 is a specific marker of t-lymphoblastic leukemia/lymphoma. American Journal of Clinical Pathology, 145(2):180–190, January 2016. URL: http://dx.doi.org/10.1093/ajcp/aqv024, doi:10.1093/ajcp/aqv024. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/ajcp/aqv024)

[11. (Zanelli2021TCell) Magda Zanelli, Giuseppe G. Loscocco, Elena Sabattini, Maurizio Zizzo, Francesca Sanguedolce, Luigi Panico, Daniela Fanni, Raffaella Santi, Cecilia Caprera, Cristiana Rossi, Alessandra Soriano, Alberto Cavazza, Alessandro Giunta, Cristina Mecucci, Alessandro M. Vannucchi, Stefano A. Pileri, and Stefano Ascani. T-cell lymphoblastic lymphoma arising in the setting of myeloid/lymphoid neoplasms with eosinophilia: lmo2 immunohistochemistry as a potentially useful diagnostic marker. Cancers, 13(12):3102, June 2021. URL: http://dx.doi.org/10.3390/cancers13123102, doi:10.3390/cancers13123102. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13123102)